Mediators of Inflammation, Prognostic Markers and Genetic Polymorphisms in Patients With Sepsis
Launched by UNIVERSITÄTSMEDIZIN MANNHEIM · Feb 16, 2012
Trial Information
Current as of April 25, 2025
Unknown status
Keywords
ClinConnect Summary
Primary Outcome Measures:
New diagnostic and prognostic markers for septic patients
Estimated Enrollment: 300 patients Study Start Date: January 2012 Estimated Study Completion Date: open Estimated Primary Completion Date: open
Intervention Details:
Procedure: vein puncture comparison of different inflammatory markers in the blood of septic patients
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • SIRS-Criteria
- • Proven Infection
- • One sepsis-induced organ-failure
- • Adults \< 18 years old
- Exclusion Criteria:
- • Anemia
- • Pregnancy
- • Blood donor in the last 3 month
About Universitätsmedizin Mannheim
Universitätsmedizin Mannheim is a leading academic medical center affiliated with Heidelberg University, dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on translational medicine, the institution integrates cutting-edge scientific discovery with patient care, fostering collaboration among multidisciplinary teams. Its state-of-the-art facilities and commitment to ethical research practices position Universitätsmedizin Mannheim as a pivotal contributor to the development of new therapies and medical technologies, ultimately enhancing patient outcomes and contributing to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Mannheim, Baden Württemberg, Germany
Patients applied
Trial Officials
Ursula Hoffmann, MD
Principal Investigator
Universitätsmedizin Mannheim
Michael Behnes, MD
Study Director
Universitätsmedizin Mannheim
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials